Unknown

Dataset Information

0

Efficacy and safety of the target-specific oral anticoagulants for stroke prevention in atrial fibrillation: the real-life evidence.


ABSTRACT: The aim of our article is to provide a concise review for clinicians entailing the main studies that evaluated the efficacy and safety of target-specific oral anticoagulants (TSOAs) for thromboembolic stroke prevention in the real-world setting. Atrial fibrillation (AF) is one of the most common supraventricular arrhythmias that requires anticoagulation therapy to prevent stroke and systemic embolism. TSOAs, dabigatran, apixaban and rivaroxaban have become available as an alternative to warfarin anticoagulation in nonvalvular atrial fibrillation (NVAF). Randomized clinical trials showed non-inferior or superior results in efficacy and safety of the TSOAs compared with warfarin for stroke prevention in NVAF patients. For this reason, the 2012 update to the European Society of Cardiology guidelines for the management of AF recommends TSOAs as broadly preferable to vitamin K antagonists (VKAs) in the vast majority of patients with NVAF [Camm et al. 2012]. Although the clinical trial results and the guideline's indications, there is a need for safety and efficacy data from unselected patients in everyday clinical practice. Recently, a large number of studies testing the efficacy and the safety of TSOAs in clinical practice have been published. The aim of our article is to provide a concise review for clinicians, outlining the main studies that evaluated the efficacy and safety of TSOAs for thromboembolic stroke prevention in the real-world setting.

SUBMITTER: Russo V 

PROVIDER: S-EPMC5315223 | biostudies-other | 2017 Feb

REPOSITORIES: biostudies-other

altmetric image

Publications

Efficacy and safety of the target-specific oral anticoagulants for stroke prevention in atrial fibrillation: the real-life evidence.

Russo Vincenzo V   Rago Anna A   Proietti Riccardo R   Di Meo Federica F   Antonio Papa Andrea A   Calabrò Paolo P   D'Onofrio Antonio A   Nigro Gerardo G   Nigro Gerardo G   AlTurki Ahmed A  

Therapeutic advances in drug safety 20161024 2


The aim of our article is to provide a concise review for clinicians entailing the main studies that evaluated the efficacy and safety of target-specific oral anticoagulants (TSOAs) for thromboembolic stroke prevention in the real-world setting. Atrial fibrillation (AF) is one of the most common supraventricular arrhythmias that requires anticoagulation therapy to prevent stroke and systemic embolism. TSOAs, dabigatran, apixaban and rivaroxaban have become available as an alternative to warfarin  ...[more]

Similar Datasets

| S-EPMC7556747 | biostudies-literature
| S-EPMC3471365 | biostudies-literature
| S-EPMC4858545 | biostudies-literature
| S-EPMC10662166 | biostudies-literature
| S-EPMC6649625 | biostudies-literature
| S-EPMC4906088 | biostudies-literature
| S-EPMC5704695 | biostudies-other
| S-EPMC9218143 | biostudies-literature
| S-EPMC3951387 | biostudies-literature
| S-EPMC6257512 | biostudies-literature